Screener
Cogent Biosciences, Inc. COGT Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $75,365 | $63,029 |
| General and administrative | 28,242 | 11,904 |
| Total operating expenses | 103,607 | 74,933 |
| Loss from operations | (103,607) | (74,933) |
| Other income: | ||
| Interest income | 7,608 | 2,952 |
| Interest expense | (1,213) | — |
| Other income (expense), net | (140) | (5) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s operating income?
- Cogent Biosciences, Inc. (COGT) reported operating income of -$103.61M in Q1 2026.
- How has Cogent Biosciences, Inc.'s operating income changed year-over-year?
- Cogent Biosciences, Inc.'s operating income decreased by 38.3% year-over-year, from -$74.93M to -$103.61M.
- What is the long-term trend for Cogent Biosciences, Inc.'s operating income?
- Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s operating income has grown at a 44.9% compound annual growth rate (CAGR), from -$75.55M to -$333.36M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Cogent Biosciences, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude